Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02409316 · ClinicalTrials.gov registry record · Phase 2
[18F]FES PET/CT in Endocrine Refractory Breast Cancer
A Phase 2 study, sponsored by University of Pennsylvania.
- Terminated
- Registry status
- Phase 2
- Development phase
- 6
- Enrollment target
NCT02409316: Clinical Trial Phase 2 study, sponsored by University of Pennsylvania.
NCT02409316 is a Phase 2 study that was terminated before completion, run by University of Pennsylvania. The registered enrollment target is 6 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02409316, a Phase 2 study, was terminated before completion, sponsored by University of Pennsylvania.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 6 participants
- Enrollment target
Study Summary
In this study, positron emission tomography (PET/CT) imaging will be used to evaluate estrogen receptor (ER) activity in sites of metastatic disease using the investigational radiotracer \[18F\]fluoroestradiol (FES).
Interventions
- DRUG [18F]FES
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2015-10-15 |
| Est. Completion | 2025-08-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02409316
The ClinicalTrials.gov registry entry for NCT02409316 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which [18F]FES is the first listed.
NCT02409316 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02409316 about?
NCT02409316 is a clinical study titled "[18F]FES PET/CT in Endocrine Refractory Breast Cancer". In this study, positron emission tomography (PET/CT) imaging will be used to evaluate estrogen receptor (ER) activity in sites of metastatic disease using the investigational radiotracer \[18F\]fluoroestradiol (FES).
What is the current status of trial NCT02409316?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 6 participants. The study started on 2015-10-15. Estimated completion is 2025-08-01.
What interventions are being tested in trial NCT02409316?
The interventions under investigation include: [18F]FES (DRUG).
Who is sponsoring clinical trial NCT02409316?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.